查詢結果分析
相關文獻
- Nasopharyngeal Carcinoma Treated with Precision-Oriented Radiation Therapy Techniques Including Intensity-Modulated Radiotherapy: Preliminary Results
- 強度調控放射線治療對鼻咽癌患者治療之評估
- 鼻咽癌使用強度調控放射治療影響耳下腺功能的因子
- 以劑量積木觀念執行鼻咽癌之電腦治療計劃
- Orbital Invasion in Nasopharyngeal Carcinoma: Evaluation with Computed Tomography and Magnetic Resonance Imaging
- 上頜掀開術切除局部復發之鼻咽癌--三例報告
- 中醫脈診儀應用於鼻咽癌患者接受放射線治療全程之研究
- Detection of Human Papilloma Virus and Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma by Polymerase Chain Reaction
- 以螢光透視錄影吞嚥檢查評估鼻咽癌患者因放射線治療所致之吞嚥功能異常
- 鼻咽癌經放射線治療後的顳葉壞死
頁籤選單縮合
題名 | Nasopharyngeal Carcinoma Treated with Precision-Oriented Radiation Therapy Techniques Including Intensity-Modulated Radiotherapy: Preliminary Results=以包含強度調控之精準導向放射治療鼻咽癌之初步結果 |
---|---|
作者 | 劉文山; 蘇茂昌; 吳銘芳; 曾顯群; 郭祥吉; Liu, Wen-shan; Su, Mao-chang; Wu, Ming-fang; Tseng, Hsien-chun; Kuo, Hsiang-chi; |
期刊 | The Kaohsiung Journal of Medical Sciences |
出版日期 | 20040200 |
卷期 | 20:2 2004.02[民93.02] |
頁次 | 頁49-55 |
分類號 | 416.879 |
語文 | eng |
關鍵詞 | 鼻咽癌; 口乾症; 強度調控放射療法; Nasopharyngeal carcinoma; Xerostomia; Intensity-modulated radiotherapy; |
中文摘要 | 本研究報告鼻咽癌患者經強度調控放射治療的初步結果及治療相關的急性反應。從 2000 年 8 月到 2001 年 5 月共有 19 位鼻咽癌患者接受以強度調控放射治療為主的治療,其中第一至第二期與第三至四期的患者各有 12 及 7 位。有六位患者在接受強度調控放射線治療前先接受了三度空間順形放射治療,劑量是 9.0-19.8葛雷。平均患者追蹤時間為 13 個月(8-18個月)。除了一位患者外,其餘第二期至第四期的患者皆在接受放射治療期間,接受兩個療程同步 cisplatin 及 5-FU 的化學治療;放療結束後再給予二至四個療程的輔助性化學治療。治療結果發現這 19 位患者原發及淋巴結的腫瘤均完全消失。在同步化學放射治療期間所發生的急性副作用包括:第三級黏膜反應有 15 位 (79%),臨床上屬第一級的口乾症有 9 位,第二級的有 9 位,第三級的有一位。本研究結果發現合併三度空間順形療法、強度調控放射療法、腔內近接療法及化學療法是治療鼻胭癌的有效方法之一。雖然此方式對於耳下腺之保護較易達成但是保護成效仍然會受腫瘤期別、頸部淋巴結位置等因素所影響,因此更多的病例與更長時間的追蹤在此方面是必須的。 |
英文摘要 | This paper reports preliminary results with intensity-modulated radiotherapy (IMRT) in nasopharyngeal carcinoma (NPC). Between August 2000 and May 2001, we treated 19 patients with NPC using IMRT. Twelve patients had stage I-II disease and seven had stage III-IV disease. Six patients received 9.0-19.8 Gy three-dimensional conformal radiotherapy (3D-CRT) before IMRT and 18 patients received a brachytherapy boost after IMRT. The mean follow-up time was 13.0 months. All patients with stage II-IV disease except one received two cycles of chemoradiotherapy with cisplatin and 5-fluorouracil (5-FU) during radiotherapy, followed by two to four cycles of chemotherapy after radiotherapy. Tumor response was assessed using clinical examination and computerized tomography or magnetic resonance imaging. The mean doses administered to the gross tumor volume and clinical tumor volume were 70.9 Gy and 63.2 Gy, respectively. The mean doses administered to the right and left parotid glands were 38.1 Gy and 38.6 Gy, respectively. All 19 patients had a complete response of primary and lymph node disease. Grade III mucositis developed during chemoradiotherapy in 15 patients (79%). In addition, clinical grade I xerostomia was recorded in nine patients, grade II in nine, and grade III in one. This study demonstrated that 3D-CRT, IMRT, intracavitary brachytherapy, and chemotherapy are effective and safe methods to treat NPC. Although IMRT treatment spared parotid gland function, its efficacy may be significantly influenced by disease stage and location of the neck lymph nodes. More cases and a longer follow-up to assess survival and complications are planned. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。